ABSTRACT. Hemolytic complement was found to be absent in the serum of an ll-yr-old girl (R.N .) with meningococcal septicemia. Cl, C4, an C2 were slightly decreased, C3 was absent, C5-C9 within the normal range. B levels immunochemically and electrophoretic mobility of B were normal. C3d was >1000% of a pooled EDTA-plasma standard indicating hypercatabolism of C3. On incubation of the patient's serum with normal human serum activation of C3 occurred even in the presence of 0.04 M EDTA. The amount of C3b generated was, however, greater without any chelating agent or in Mg-EGTA. On gel filtration of the serum two protein containing peaks were found to be responsible for activation of C3: the IgG containing peak was able to activate C3 in normal human serum without chelating agents and in Mg-EGTA but not in the presence of EDTA. The IgM-containing peak activated the third component of complement even in the presence of EDT A. The factor responsible for this phenomenon was termed C3 converting factor (C3 CoF). The IgG fraction of the patients serum caused activation of C3 in Mg-EGTA. However, in the presence of EDTA no activation of C3 could be induced even if physiological concentrations of the patients IgG were added to normal human EDTAplasma. Thus the activity of the patient's IgG did not differ from typical C3 nephritic factor. The decay ofC2 in EAC42 intermediates in the presence of the patient's IgG was uninfluenced indicating that it did not carry autoantibody activity against the classical pathway convertase C4b,2a, an activity recently termed NFc. As the ability of the patient's serum to activate C3 in the presence of excess EDTA was still unexplained further analyses were performed. C3 CoF was found to be a {32-euglobulin and could be separated from IgG by anion exchange chromatography following euglobulin precipitation . C3 conversion with this material was independent from Ca 2 + and Mg 2 +. It was partly heat resistant at 56°C and could not be inhibited by soy bean trypsin inhibitor at 5 mg/ml. In contrast, DFP at 5 mM concentration lead to approximately 50% inhibition indicating that C3 CoF might be a serine protease. Treatment of patient's EDTA plasma with anti-C3 or anti-B totally eliminated C3 CoF activity while antialbumin, anti-124 WAHN ET AL. the presence of both Ca 2 + and Mg 2 +. C3 Nef has been found in sera of patients with MPGN, partial lipodystrophy, and meningococcal meningitis (8) (9) (10) . It is an IgG-autoantibody directed against C3b,Bb (11, 12)which stabilizesthe enzyme and prevents its intrinsic decay (13) . C3 Nef requires Mg 2 + for its action. An analogue directed against the classical pathway convertase C4b,2a has been detected in serum of a patient with acute glomerulonephritis (NFc, 1). It is probably identical with the F-42 autoantibody found in some SLE-sera (14, 15) . It seems to prevent the intrinsic decay of C4b,2a as well as the extrinsic decay mediated by C4 binding protein (16) . In addition, C4b in the stable convertase C4b,2a is protected from the proteolytic action of factor I (16). C4b,2a, thus stabilized, may activate C3 even in EDTA (17) Thus, except for the nephritic factor of the classical pathway NFc which is an IgG, all the known C3 converting activities depend on Mg 2 +. Herein we describe a factor (C3 CoF) which does not require divalent cations and is composed of C3, B, and IgG.
CASE REPORT
The family history of patient R.N. was unremarkable as was her own history until the age of II yr. Ten days prior to admission to the hospital she had an episode of otitis media which was treated with amoxycillin for 3 days. One week later she became febrileagain and began to vomit. In addition pain and tenderness of the left knee and some finger joints occurred.
On physical examination after admission she had a temperature of 40.4°C and a generalized maculopapulour, partially petechial rash. We noticed marked lymphadenopathy and slight hepatosplenomegaly. Meningeal signs were absent.
Laboratory (24 PMNL, 6 mononuclear cells),cultures sterile. Evidence of renal disease was found neither at the time of admission nor during the 3 yr observation period following recovery.
Treatment was initiated with ampicillin (300 mg/kg body weight/day) and tobramycin (5 mg/kg body weight/day) and continued with penicillin G after identification of meningococci. Clinical improvement and normal temperature was achieved within 24 h. After 10 days of treatment antibiotic therapy was discontinued.
After complete recovery from her illness (for now approximately 3 yr) CH 50-and C3-levels remained undetectable and therefore further analyses of the complement system were performed (see "Results"). Analyses of the parent's sera revealed normal total hemolytic complement activity and normal levels for C3.
MATERIALS AND METHODS
Sera. Venous blood was obtained and allowed to clot for 30-60 min at room temperature. After centrifugation serum was kept in aliquots at -70°C until use. EDTA-plasma was prepared similarly using EDTA-coated tubes. (NHS and NHPI) was obtained from 30 healthy volunteers from the clinic staff and pooled. These pools served as reference standards for all complement determinations.
Titrations of total hemolytic complement and individual components were performed according to Mayer (20) . Cellular intermediates EA, EAC4, EACl, and EACl,4 were prepared in our laboratory as described (21) . EACI-7 and functionally purified C components were purchased from Cordis (Miami, FL) or prepared according to Rapp and Borsos (22) . Alternative pathway lysis was measured using rabbit erythrocytes in Mg-EGTA buffer according to Platts-Mills and Ishizaka (23) .
Immunochemical determinations of C3, C4, and B were performed by single radial immunodiffusion according to Mancini et al. (24) using commercially available plates (Behring,Marburg, FRG). Clq, I, H, and P were quantitated by the same technique. Antisera to Clq, I, and H were obtained from Miles (Elkhart, IN), to P from Atlantic Antibodies (Scarborough, ME). C3d was measured in EDTA-plasma by rocketelectrophoresis as recently described (21) . Prior to the run into an anti-C3d antibody containing gel EDTA-plasma had been treated with 12% polyethyleneglycol6000 to precipitate C3 and C3b reactive with the anti-C3d antibody. The antiserum to C3d was obtained from DAKO (Copenhagen, Denmark). C3b was detected by crossed IEP as described by Weeke (25) . The antiserum to C3 was purchased from Miles. Cleavage products of factor B were identified by IEP (26) using monospecific antiserum to B from Behring. Normal EDTA-plasma served as a negative control and zymosan-activated serum (10 mg/rnl, 30 min at 37°C) as a positive control.
If not specifically mentioned in the text all incubations were performed for 30 at 3r e. For heat-inactivation sera were incubated for 30 min at 56°e. A tandem-crossed IEP was performed to determine the electrophoretic mobility of residual C3-antigen present occasionally in some of the patient's reconvalescent sera. For this purpose two wellswere filled on the same gel prior to the run in the first dimension. Well I contained RNS, well 2 NHS I: 10 diluted after a 5-min activation with heat-AHG at 2 mg/ml and 37°e. This activated serum served as a source for C3 and C3b. AHG was prepared as described (21) .
C3 CoF electrophoretic mobility was determined following electrophoresis in 1% agarose in barbital buffer pH 8.6 shown in scheme 1. Following 2 h electrophoresis at 2 V/cm the gel in the center of the slide (containing separated proteins to I00~I RNS) was cut into l-mm slices and each slice added to 0.1 mlofPBS. Fractions were eluted from the agarose by shaking for 1 h at room temperature. C3 CoF assay was performed with all fractions. Next horse antiserum to whole human serum (Behring) was added to the troughs and diffusion was allowed for 24 h in a moist chamber before the slide was washed and the precipitates stained with Coomassie blue. C3 CoF mobility was determined by comparing the maximum of C3 conversion in EDTA with the precipitin arcs of regular IEP. For determination of C3 CoF molecular weight I ml of patient's serum was separated by gel filtration using HPLC equipment (LKB, Bromma, Sweden) and a TSK-G SW 4000 blue column (7.5 x 600 mm, LKB). One-ml fractions were collected, and all protein-containing fractions were assayed for C3-converting activity in Mg-EGTA and EDTA as well as for IgG and IgM as internal marker proteins.
The patient's IgG-fraction and normal IgG were isolated by ammonium sulphate precipitation and DEAE 52 anion exchange chromatography as described by Johnstone and Thorpe (27) . Further purification was achieved by gel filtration using a Sephadex G-200 column (2.5 x 30 em) and by affinity chromatography using a Sepharose CL 4B-protein A column (13 x 55 mm, Pharmacia, Freiburg, FRG) according to Patrick and Virella (28) . With this material only one precipitin arc was found on IEP against anti-whole human serum and anti-human IgG (from rabbits, Behring). IgG-levels were determined by radial immunodiffusion using commercial plates (Behring) and adjusted to C3 CONVERTING FACfOR 125 approximately 12 mg/rnl by ultrafiltration using Amicon UM 30 (Lexington, MA) membranes. These IgG-fractions were used for crossed IEP experiments, the NFc and C3 NeF assay.
Euglobulin was precipitated by dialysis of5 ml of the patient's serum against 2 mM phosphate buffer pH 7.0, once for 2 hand, after buffer exchange , for 16 h at 4· C. The euglobulin obtained was washed once using the same butTer. Following this precipitation step C3 CoF could not be dissolved at normal ionic strength and normal pH. It was only partly soluble in 0.5 ml of 0.2 M carbonate-bicarbonate butTer pH 9.6. Insoluble material was removed by centrifugation. Dissolved supernatant contained only 20% of the total initial C3 CoF activit y. It was next dialyzed against 0.07 M phosphate butTer pH 6.3 for 2 h at 4°C before it was applied to a Ultropac TSK DEAE column (150 x 7.5 mm , LKB) equilibrated with the same butTer. After elution ofthe IgGpeak (void volume) using this buffer the " non-IgG" fraction was eluted by markedly increasing the ionic strength using I M NaCI dissolved in starting butTer.Protein concentrations were recorded by measuring absorbance at 280 nm. The major peaks were pooled , concentrated by ultrafiltration, and assayed for IgG, C3 NeF, and C3 CoF activity by crossed IEP against anti-C3 antiserum after incubation of the fractions with NHS and the required chelating agent. In a representative experiment the IgG fraction after ultrafiltration had a volume of 0.35 ml and a protein content of 0.67 g/dl, the non-IgG fraction a volume of 0.8 ml, and a protein content of 0.11 g/dl, The overall yield for C3 CoF in the latter fraction was approximately 8%, the specific activity was about 8-fold higher than in original patient's serum.
C4b,2a stabilization assay. Basically the method of Halbwa chs et al. (I) was used. Partiall y purified components CI and C2
were prepared as described by Rapp and Borsos (22) . C2 was oxidized.
Incubations . In the standard assay for C3 CoF activity I volume of the patient's serum was mixed with EDTA at a final concentration of 0.04 M before I volume of NHS was added . The mixture was incubated for 30 min at 37" C before it was subjected to crossed IEP against anti-C3 antibody. If fractions eluted from the columns were tested for C3 CoF a 10:I or 20: I ratio (volume fraction : volume NHPI) was chosen to compensate dilution etTects. EDTA was always added at a final concentration of 0.04 M. If incubations were performed in Mg-EGTA butTer a 0.02 M concentration ofEGTA and 0.005 M for Mg 2 + was used. The temperature dependence of C3 CoF action was determined by performing the standard assay at 0, 10,20,30, and 37" C.
To find out if SBTI (Sigma, Munich, FRG) could diminish C3 CoF activity it was added at various concentrations between 0.1 and 5 mg/rnl to the standard reaction mixture prior to incubation at 37°C. The same procedure was used for DFP (Sigma).
C3 NeF activity was measured by activation of C3 in NHS by either heat-inactivated patient's serum or purified RN-IgG in Mg-EGTA butTer using crossed IEP.
Next attempts were made to eliminate C3 CoF from RNS by addition of monospecific antisera. The following antibodies were used (if concentration was required it was done by ultrafiltration, dilutions were made in PBS): IgG-fraction of rabbit anti-human IgG (h-and 1-chain, Cappell Lab ., concentrated 10-fold), IgGfraction of goat anti-human C3 (Cappell , diluted 1:30), IgG fraction ofgoat anti-human C4 (Beckmann Instr., Munich, FRG, concentrated 4-fold), IgG fraction of rabbit anti -human factor B (Behring , concentrated 8-fold, sheep anti -human C2 (Seward Lab., London, England). Two volumes of RNS were mixed with 1 volume of 0.2 M EDTA before 2 volumes of antiserum were added.
After 15 min at room temperature and 15 min at O· C the precipitates were removed by centrifugation. In the control experiments physiological saline, nonimmune rabbit IgG and an IgG fraction of rabbit anti-human albumin (Behring , concentrated 8-fold) was used instead of antiserum. The remaining supernatants (under the conditions chosen free ofthe precipitated Scheme I. Set up of wells in agarose for determ ination of C3 CoF electrophoretic mobility.
antigen by double ditTusion, except for IgG and albumin) were next added to NHPI at a 2: I (v/v) ratio and the mixture incubated for 30 min at 37" C before crossed IEP against anti-C3 was performed (C3 CoF assay). The areas under C3 and C3b peaks were calculated planimetrically.
Affinity chromatography. Because IgG could not be completely eliminated by immune precipitation an affinit y column was set up: 120 mg of IgG-fraction of rabbit anti-human IgG (Cappell) were coupled to CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) at 7 mg/rnl gel according to the instructions of the manufacturer. The resulting column size was 16 x 65 mm. One-half ml of RNS was added and eluted with PBS at 30 ml/h. The material excluded from the column was concentrated by ultrafiltration to 3.29 g/dl and assayed for IgG, C3 NeF, and C3 CoF.
RESULTS

R esults of hemolytic titrations.
Total hemolytic complement was hardly detectable and alternative pathway lysis undetectable. Components Cl , C4, C2, and C5 were decreased and C3 was present in traces immunochemically and functionally. These traces could be identified as native C3 by tandem crossed IEP. C7 was slightly elevated and the other components were within the normal range [normal ranges have been reported (21)]. B, P, I, and H were normal (immunochemically) and C3d-Ievels extremel y elevated (above upper level of our standard curve) . The hemolytic activity of CI , C4, and C2 was undetectable if EACl42-intermediates were not washed with ggvb 2 + before C-EDTA was added as a source ofC3-C9. Figure 1 shows the results of crossed IEP and IEP of C3 and B, respectively, in NHS following incubation with the patient's serum under various conditions. In the presence of Mg-EGTA the electrophoretic mobilities of both C3 and B were shifted to the position of the respective activated component. In the presence of EDTA, however, C3 was activated while B retained its normal electrophoretic mobility. This cleavage of C3 in normal human EDTA-plasma induced by RNS led to the definition of C3 converting factor, C3 CoF (Fig. 2) . B cleavage could be induced in RNS ifC3 (3 CH 50 U/ml, final mixture) was added prior to incubation instead ofNHS as a source of C3. In contrast to cleavage ofC3, however, B cleavage depended on the presence of Mg 2 + (Fig. 3) suggesting activation via the alternative pathway. Heat stability of the suspected activator of C3 was tested and the results are given in Table 1 . If NHS is incubated with ggvb?" alone for 30 min at 37" C total hemolytic complement and hemolytic C3 are slightly decreased compared to the non incubated control (data not shown). Incubation of NHS with heatinactivated NHS led to similar results. On incubation of NHS with heat-inactivated RNS an almost complete consumption of total hemolytic complement and C3 was observed. If EDTA was added to the latter mixture intermediate values for CH 50 and C3 were obtained. Further experiments with heat-inactivated RNS were carried out by crossed IEP (Fig. 4) . We notice that incubation of NHS alone leads to some activation of C3 (a) .
Addition of RNS markedly increases the amount of C3b generated (b) . Results in Mg-EGTA (c) ditTer only slightly from (b).
In EDTA, however, most ofC3 activation is blocked (d) We initially expected only one activator of C3 to be present. Thus, to estimate the molecular weight of this activator RNS was subjected to gel filtration. After separation individual fractions were incubated with NHS and either Mg-EGTA or EDTA for 30 min at 37" C. After crossed IEP against anti-C3 two peaks exhibited activating properties for C3 in vitro. In Mg-EGTA C3 was activated in the IgM and IgG region while in EDTA only the IgM-containing fraction was active (Fig. 5) . Fig, 3 . rEP to detect B activation products following incubation for 30 min at 37" C of RNS with saline or functionally purified C3 (3 CH 50 Vlml ) in Mg-EGTA (a) or in EDTA (b). After addition ofC3 B can be activated in Mg-EGTA (arr ow).
RNS+C3 '
Further experiments were carried out with patient's IgG and normal IgG isolated under identical conditions. Figure 6 shows that incubation of RN-IgG with NHS induces significant activation of C3. This was observed without chelating agents and in Mg-EGTA. However, if we used EDTA instead no activation of C3 could be achieved. Thus, the activating properties of RN-IgG were not identical with the activity attributed to C3 CoF. RNIgG markedly activated C3 in Mg-EGTA buffer and was, thus, undistinguishable from C3 NeF. C3 CoF was still unidentified.
C3 CONVERTING FACTOR 127 using euglobulin precipitation and anion exchange chromatography on DEAE 52 using a discontinuous salt gradient to elute fractions. The elution profile is depicted in Figure 8 . Peak I contained 630 mg/dl of protein and 463 mg/dl of IgG and Since the patient's serum was able to convert C3 in NHS during incubation in EDTA there was a chance that C3 CoF was identical with an already stabilized classical pathway convertase C4b,2a. Therefore we analyzed whether preformed C4b ,2a was stabilized by RN-IgG as reported (1,16). EACI42 were prepared, washed, and resuspended in EDTA-buffer. One part of resuspended cells was incubated in the presence of RN-IgG, another part with identical concentration of normal IgG isolated in parallel. Samples were taken at intervals, washed , and lysed by the addition of guinea pig serum in 0.0 I M EDTA. The decay ofC2 in the presence of RN-IgG and N-IgG was identical. NFc activity in patient's IgG was therefore excluded. However, C3 CoF could still be a prestabilized C3 convertase ofeither pathway. This possibility was next evaluated using monospecific antisera.
If RNS was treated with monospecific antisera prior to C3 CoF assay some antisera markedly reduced it's activity (the amount of C3b generated is expressed as percent C3b area divided by C3 + C3b area). After treatment of RNS with saline 32% C3b were generated, with nonimmune rabbit IgG 35%, and with antialbumin 36%. With anti-C4 it was 34%, with anti-C2 29%, with anti-IgG 13%. After treatment with anti-C3 or anti-B antibody C3 CoF in the supernatant was no longer detectable. These data suggest the presence of C3, B, and IgG antigens in C3 CoF.
As IgG could not completely be precipitated by monospecific antibody it was absorbed out by affinity chromatography. The absorbed material had a protein concentration of 3.29 g/dl. IgG was below the level of detection by radial immunodiffusion (0.8 mg/dl) and C3 NeF and C3 CoF were absent.
On preparative electrophoresis in agarose C3 CoF activity was detected in the ,B2-region. This also supported the concept that it is no IgG. Of the five temperatures tested most conversion of C3 could be induced at 37" C ( Fig. 7) indicating that C3 CoF does not activate C3 in the cold.
We attempted to separate C3 NeF from C3 CoF. We succeeded CoF. The patient's euglobulin is dissolved and applied to a DEAE column (as described under "Materials and methods") equilibrated with 0.1 M phosphate buffer pH 7.2. After elution of the first major peak (mainly IgG) the starting buffer is replaced by a 0.1 M phosphate buffer containing 1 M sodium chloride (the buffer exchange is indicated by the arrow). All three peaks were pooled, concentrated by ultrafiltration, and assayed for IgG, C3 NeF, and C3 CoE Peak I contained mainly IgG and C3 NeF activity but was devoid ofC3 CoF. Peak II contained traces ofIgG as well as C3 NeF but no C3 CoF. Peak III contained only traces of IgG but most of C3 CoF activity. Pool III also activated C3 in Mg-EGTA. activated C3 in Mg-EGTA but not in EDTA. Peak II contained only little protein and no C3 activator. Peak III contained (after repeated ultrafiltration) 580 mg/dl of protein and only traces of IgG but activated C3 in the presence of 0.04 M EDTA. This strongly suggeststhat C3 CoF is no IgG.
DISCUSSION
In an ll-yr-old girl with meningococcal septicemia hypercatabolism of C3 with undetectable C3 and extremely high levels of C3d persisted as long as 3 yr after complete recovery. This hypercatabolism was due to the presence of two different C3 activators with different biochemical properties.
The first activator was found to be heat stable, Mg 2+ dependent, and did copurify with IgG. It markedly activated C3 in Mg-EGTA. The decay of the classical pathway convertase C4b,2a, in the presence ofRN-IgG, was unaffected. Thus, this first activator did not raise our interest because it seemed to be a well known activator of C3, C3 nephritic factor C3 NeF.
As C3 CoF action is independent from divalent cations it must be different from all Mg 2+-dependent activators described. Theoretically, it could be a stabilized C3 convertase of either pathway. If C3 CoF was identical with NFc-stabilized C4b,2a one should expect at least some free circulating NFc in the patients IgG-fraction as described (1); but no such activity was found. In addition, we failed to eliminate C3 CoF by immunoprecipitation with anti-C4 or anti-C2. In contrast, it was completely eliminated by immunoprecipitation with anti-C3 and anti-B and partly eliminated with anti-IgG. Using an anti-IgG affinity column C3 CoF was completely absorbed out together with IgG and C3 NeF. The most plausible explanation for these results is the simultaneous occurrence of free C3 NeF with a C3 NeF-stabilized C3 CONVERTING FACTOR 129 AP C3 convertase (C3 CoF). If this is so, it would indicate that if the regular "negative" controls for C3 NeF assays are "slightly positive" C3 CoF may be present. Future studies will have to focus on the mechanism that allows the formation and persistence of C3 CoF.
Sensitivity of C3 CoF to inhibition with DFP further supports the concept that it is a serine protease despite the fact that in serum only 50% inhibition could be achieved while Medicus et al. (29) achieved 80% in a serum-free system. In serum DFP might be absorbed to other proteins. An interesting observation was the absence of hemolytic C I, C4, and C2 in RNS when we applied the complement technology generally used. This technology works on the assumption that lysis of EAC142 can be achieved by the addition of C-EDTA as a source of C3-C9. EDTA is said to prevent generation of C3 convertases of either pathway. Serial dilutions of RNS containing C3 CoF obviously activated guinea pig C3 making a C5-C9 reagent of C-EDTA which was unable to lyse EACI42 cells. Washing EACI42 intermediates prior to the addition of C-EDTA eliminated C3 CoF and preserved guinea pig C3 hemolytic activity allowing correct titration ofCI, C4, and C2.
While C3 NeF induced activation ofC3 and B without chelating agents and in Mg-EGTA, B remained uncleaved in EDTA. This indicates that C3 NeF requires newly formed C3b,Bb for its action while C3 CoF seems to act independently from either convertase. B in RNS was present in normal concentrations and , despite the presence of C3 NeF, had normal electrophoretic mobility. This can easily be explained as follows. Initiation of the alternative pathway of complement requires native C3 for formation of C3 (H 20) . This so-called C3b-like C3 reacts with B in the presence of Mg 2 + and factor D to C3 (H 20) ,Bb. B is activated during this step. The patient's serum was devoid of C3 so that initiation of the AP was impossible. However, if additional C3 was provided by either NHS or isolated C3 in the presence of Mg 2 + , AP activation was facilitated. In EDTA, however, only C3 CoF acted upon C3 to form C3a and C3b while cleavage of B was prevented.
In summary, it seems that under conditions that we are unsure ofC3 NeF binds to C3b,Bb to form a chronically circulating AP C3 concertase (C3 CoF). C3 CoF, once formed, acts independently from divalent cations. Its presence should be considered if "negative" controls for C3 NeF turn out to be positive, or if hemolytic titrations of C I, C4, and C2 are close to zero in the presence of normal amounts of antigens.
